Fundraising FoxLongwood Fund — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLuma GroupSofinnova VenturesBAM ElevateForbionNovo Holdings+2 more
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsAgent CapitalGimvMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture Investments+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.